141 related articles for article (PubMed ID: 27473490)
21. Forced Degradation of Monoclonal Antibodies After Compounding: Impact on Routine Hospital Quality Control.
Jaccoulet E; Daniel T; Prognon P; Caudron E
J Pharm Sci; 2019 Oct; 108(10):3252-3261. PubMed ID: 31201907
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies as therapeutic agents for cancer.
Harris M
Lancet Oncol; 2004 May; 5(5):292-302. PubMed ID: 15120666
[TBL] [Abstract][Full Text] [Related]
23. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients.
Kang HJ; Park JS; Kim DW; Lee J; Jeong YJ; Choi SM; Lee SM; Yang SC; Yoo CG; Kim YW; Han SK; Yim JJ
Respir Med; 2012 Mar; 106(3):443-50. PubMed ID: 22154502
[TBL] [Abstract][Full Text] [Related]
24. Application of affinity capillary electrophoresis for charge heterogeneity profiling of biopharmaceuticals.
Hutanu A; Kiessig S; Bathke A; Ketterer R; Riner S; Olaf Stracke J; Wild M; Moritz B
Electrophoresis; 2019 Nov; 40(22):3014-3022. PubMed ID: 31560789
[TBL] [Abstract][Full Text] [Related]
25. Imaged capillary isoelectric focusing associated with multivariate analysis: A powerful tool for quality control of therapeutic monoclonal antibodies.
Tardif C; Jaccoulet E; Bellec JF; Surroca Y; Talbot L; Taverna M; Smadja C
Talanta; 2023 Aug; 260():124633. PubMed ID: 37172435
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts.
Tai CJ; Wang H; Wang CK; Tai CJ; Huang MT; Wu CH; Chen RJ; Kuo LJ; Wei PL; Chang YJ; Chang CC; Chiou HY; Wu CJ
Clin Exp Med; 2017 May; 17(2):141-150. PubMed ID: 26995061
[TBL] [Abstract][Full Text] [Related]
27. Characterization of cetuximab Fc/2 dimers by off-line CZE-MS.
François YN; Biacchi M; Said N; Renard C; Beck A; Gahoual R; Leize-Wagner E
Anal Chim Acta; 2016 Feb; 908():168-76. PubMed ID: 26826699
[TBL] [Abstract][Full Text] [Related]
28. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
[TBL] [Abstract][Full Text] [Related]
29. Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products.
Gahoual R; Beck A; Leize-Wagner E; François YN
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():61-78. PubMed ID: 27265157
[TBL] [Abstract][Full Text] [Related]
30. [Combination therapy of targeted drugs].
Saijo N
Nihon Rinsho; 2012 Nov; 70 Suppl 8():652-7. PubMed ID: 23513917
[No Abstract] [Full Text] [Related]
31. Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies.
Goyon A; Excoffier M; Janin-Bussat MC; Bobaly B; Fekete S; Guillarme D; Beck A
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Oct; 1065-1066():119-128. PubMed ID: 28961486
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of capillary zone electrophoresis for charge heterogeneity testing of monoclonal antibodies.
Moritz B; Schnaible V; Kiessig S; Heyne A; Wild M; Finkler C; Christians S; Mueller K; Zhang L; Furuya K; Hassel M; Hamm M; Rustandi R; He Y; Solano OS; Whitmore C; Park SA; Hansen D; Santos M; Lies M
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Mar; 983-984():101-10. PubMed ID: 25637812
[TBL] [Abstract][Full Text] [Related]
33. Simulation program of a cytotoxic compounding robot for monoclonal antibodies and anti-infectious sterile drug preparation.
Deljehier T; Bouguéon G; Heloury J; Moreno V; Berroneau A; Crauste-Manciet S
J Oncol Pharm Pract; 2019 Dec; 25(8):1873-1890. PubMed ID: 30651029
[TBL] [Abstract][Full Text] [Related]
34. Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab.
Butterfield JT; Kim H; Knauer DJ; Nevala WK; Markovic SN
Sci Rep; 2017 Nov; 7(1):14476. PubMed ID: 29101359
[TBL] [Abstract][Full Text] [Related]
35. A novel model for the pharmacokinetic studies of bevacizumab and etanercept in healthy volunteers and patients.
Li M; Qiang W; Hu L; Wang L; Cheng Z
Biochem Pharmacol; 2017 Dec; 145():169-177. PubMed ID: 28822784
[TBL] [Abstract][Full Text] [Related]
36. Crystalline monoclonal antibodies for subcutaneous delivery.
Yang MX; Shenoy B; Disttler M; Patel R; McGrath M; Pechenov S; Margolin AL
Proc Natl Acad Sci U S A; 2003 Jun; 100(12):6934-9. PubMed ID: 12782786
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic monoclonal antibodies in ophthalmology.
Rodrigues EB; Farah ME; Maia M; Penha FM; Regatieri C; Melo GB; Pinheiro MM; Zanetti CR
Prog Retin Eye Res; 2009 Mar; 28(2):117-44. PubMed ID: 19114125
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapies for cancer 2004.
Ross JS; Schenkein DP; Pietrusko R; Rolfe M; Linette GP; Stec J; Stagliano NE; Ginsburg GS; Symmans WF; Pusztai L; Hortobagyi GN
Am J Clin Pathol; 2004 Oct; 122(4):598-609. PubMed ID: 15487459
[TBL] [Abstract][Full Text] [Related]
39. Integrated microreactor for enzymatic reaction automation: An easy step toward the quality control of monoclonal antibodies.
Ladner Y; Mas S; Coussot G; Bartley K; Montels J; Morel J; Perrin C
J Chromatogr A; 2017 Dec; 1528():83-90. PubMed ID: 29122286
[TBL] [Abstract][Full Text] [Related]
40. Analysis of inline-filter blockage with trastuzumab formulation using scanning-electron microscopy.
Ogawa C; Inoue M; Yatabe M; Nagayama Y; Gomi H; Nakadate K; Adachi S; Yachi Y; Itoh T
Biomed Pharmacother; 2019 Apr; 112():108711. PubMed ID: 30970515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
